Drugmakers relying on acquisitions to replenish their pipeline are increasing bids for biotech firms, driving the average premium higher, according to Bloomberg data. For biotech takeover targets valued at greater than $500 million, the premium over 20-day average share price is 71% this year, the most in at least 12 years.

Related Summaries